Targeting CDK4/6 in patients with cancer.

[1]  D. Juric,et al.  Abstract P3-14-01: Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis , 2016 .

[2]  A. Bardia,et al.  Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2– advanced breast cancer , 2016 .

[3]  S. Loi,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[4]  N. Sharpless,et al.  Forging a signature of in vivo senescence , 2015, Nature Reviews Cancer.

[5]  M. Goetz,et al.  A phase Ib study of abemaciclib with therapies for metastatic breast cancer. , 2015 .

[6]  M. Ellis,et al.  Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results , 2015 .

[7]  Jian-Bing Fan,et al.  CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells , 2015, Cell stem cell.

[8]  P. Queirolo,et al.  BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies , 2015, OncoTargets and therapy.

[9]  J. Malvehy,et al.  Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. , 2014, Journal of the American Academy of Dermatology.

[10]  P. Wen,et al.  Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer , 2014 .

[11]  R. Finn,et al.  Abstract 1321: Identification of markers of sensitivity and resistance to palbociclib (PD0332991) in melanoma , 2014 .

[12]  R. Finn,et al.  Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer , 2014 .

[13]  D. Juric,et al.  Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Xiangyi Zheng,et al.  MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6 , 2014, Journal of experimental & clinical cancer research : CR.

[15]  B. Geoerger,et al.  455PPHASE I STUDY OF LEE011 (CDK4/6 INHIBITOR) IN PATIENTS WITH MALIGNANT RHABDOID TUMORS, NEUROBLASTOMA, AND CYCLIN D-CDK4/6 PATHWAY-ACTIVATED TUMORS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  E. Knudsen,et al.  CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer , 2014, Oncotarget.

[17]  G. Demetri,et al.  Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo , 2014, Molecular Cancer Therapeutics.

[18]  J. Lehár,et al.  CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. , 2014, Cancer cell.

[19]  E. Knudsen,et al.  CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models , 2014, Genes & cancer.

[20]  S. Fox,et al.  Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines , 2014, Pigment cell & melanoma research.

[21]  P. Iversen,et al.  Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine , 2014, Investigational New Drugs.

[22]  L. Gelbert,et al.  Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts , 2014, Clinical Cancer Research.

[23]  G. Shapiro,et al.  A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. , 2014 .

[24]  P. Wen,et al.  LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. , 2014 .

[25]  J. Blay,et al.  Identifying actionable targets in advanced cancer patients: Preliminary results from the Profiler program. , 2014 .

[26]  J. Sosman,et al.  A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity. , 2014 .

[27]  F. Kaye,et al.  A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A. , 2014 .

[28]  P. Wen,et al.  Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. , 2014 .

[29]  D. Heitjan,et al.  A phase I trial of palbociclib and paclitaxel in metastatic breast cancer. , 2014 .

[30]  Frederick S. Vizeacoumar,et al.  RB1 Status in Triple Negative Breast Cancer Cells Dictates Response to Radiation Treatment and Selective Therapeutic Drugs , 2013, PloS one.

[31]  T. Burke,et al.  The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation , 2013, Molecular Cancer Therapeutics.

[32]  W. Sellers,et al.  Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer. , 2013 .

[33]  K. Cole,et al.  Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma , 2013, Clinical Cancer Research.

[34]  H. Saavedra,et al.  Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis , 2013, Cell Division.

[35]  L. Qin,et al.  Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Wen,et al.  A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. , 2013 .

[37]  D. Heitjan,et al.  A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer. , 2013 .

[38]  J. Dempsey,et al.  Abstract LB-122: LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer. , 2013 .

[39]  F. Kaye,et al.  Abstract 693: Inhibitory effect of the CDK4/6 inhibitor, PD 0332991, is enhanced by mTOR inhibition in Non-Small Cell Lung Cancer (NSCLC). , 2013 .

[40]  W. Klapper,et al.  Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network , 2013, Leukemia & lymphoma.

[41]  F. Westermann,et al.  CDK4 inhibition restores G₁-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage , 2013, Cell cycle.

[42]  Y. Yoshioka,et al.  Radiotherapy targeting cancer stem cells: current views and future perspectives. , 2013, Anticancer research.

[43]  Sung Dae Kim,et al.  A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy. , 2013, Biochemical and biophysical research communications.

[44]  E. Reddy,et al.  CDK4: A Key Player in the Cell Cycle, Development, and Cancer. , 2012, Genes & cancer.

[45]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[46]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[47]  Y. Kuwahara,et al.  Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells , 2012, Oncogenesis.

[48]  A. D. Van den Abbeele,et al.  Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. , 2012, Blood.

[49]  Charles M. Perou,et al.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. , 2012, Journal of the National Cancer Institute.

[50]  Xiangyi Zheng,et al.  Cyclin‐dependent kinase 4 is a novel target in micoRNA‐195‐mediated cell cycle arrest in bladder cancer cells , 2012, FEBS letters.

[51]  W. Koch,et al.  CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy , 2012, Cell cycle.

[52]  L. Butler,et al.  Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors , 2012, Cell cycle.

[53]  E. Hoster,et al.  Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network , 2011, Leukemia & lymphoma.

[54]  K. Flaherty,et al.  Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[55]  S. Gygi,et al.  A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. , 2011, Cancer cell.

[56]  Gaëlle Pérot,et al.  The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well‐differentiated and dedifferentiated liposarcoma oncogenesis. An analysis of 104 tumors , 2011, Genes, chromosomes & cancer.

[57]  A. Azzam,et al.  Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer , 2011, Scandinavian journal of clinical and laboratory investigation.

[58]  P. Houghton,et al.  Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. , 2011, Biochemical and Biophysical Research Communications - BBRC.

[59]  D. Yee,et al.  Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. , 2011, Endocrine-related cancer.

[60]  Robert L. Sutherland,et al.  Cyclin D as a therapeutic target in cancer , 2011, Nature Reviews Cancer.

[61]  S. Singer,et al.  Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma , 2011, Current opinion in oncology.

[62]  R. Clarke,et al.  Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. , 2011, Endocrine-related cancer.

[63]  V. Velculescu,et al.  Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer , 2011, Clinical Cancer Research.

[64]  A. Wiestner,et al.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. , 2011, Blood.

[65]  Yonghong Xiao,et al.  Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM , 2010, Proceedings of the National Academy of Sciences.

[66]  B. Weissman,et al.  Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism. , 2010, Cancer research.

[67]  K. Coulonval,et al.  Rb inactivation in cell cycle and cancer: The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase , 2010, Cell cycle.

[68]  T. Shaikh,et al.  Genomic Analysis Using High-Density Single Nucleotide Polymorphism-Based Oligonucleotide Arrays and Multiplex Ligation-Dependent Probe Amplification Provides a Comprehensive Analysis of INI1/SMARCB1 in Malignant Rhabdoid Tumors , 2009, Clinical Cancer Research.

[69]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[70]  Jan Koster,et al.  Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. , 2008, Cancer research.

[71]  E. Fuchs,et al.  NFATc1 Balances Quiescence and Proliferation of Skin Stem Cells , 2008, Cell.

[72]  C. Sander,et al.  Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. , 2007, Cancer research.

[73]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  P. Hinds,et al.  From Cell Cycle to Differentiation: An Expanding Role for Cdk6 , 2006, Cell cycle.

[75]  A. Rosenwald,et al.  Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  M. Mansukhani,et al.  Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[77]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[78]  Liang Zhu,et al.  Cell Cycle Arrest and Repression of Cyclin D1 Transcription by INI1/hSNF5 , 2002, Molecular and Cellular Biology.

[79]  M. Barbacid,et al.  Cyclin D-dependent kinases, INK4 inhibitors and cancer. , 2002, Biochimica et biophysica acta.

[80]  F. Hodi,et al.  Molecular genetics of familial cutaneous melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  J. Bartek,et al.  High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. , 1996, Cancer research.

[82]  J. Geradts,et al.  High frequency of aberrant p16(INK4A) expression in human breast cancer. , 1996, The American journal of pathology.

[83]  J. Bartek,et al.  Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. , 1995, Cancer letters.

[84]  J. Bartek,et al.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.

[85]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[86]  M. Malumbres,et al.  CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. , 2015, Blood.

[87]  M. Dickson.  Molecular Pathways Molecular Pathways : CDK 4 Inhibitors for Cancer Therapy , 2014 .

[88]  N. Hayward,et al.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.